F Opdam, MD, PhD
Antoni van Leeuwenhoek/The Netherland Cancer Institute · The Netherlands Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name F Opdam, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:59 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05518799 · CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid TumoursThe Netherlands Cancer Institute · completed · Prostate Cancer, Solid Tumor, Adult · principal investigator
- Ph1/Ph2NCT02450656 · Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung CancerThe Netherlands Cancer Institute · unknown · Colorectal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms · principal investigator
- Ph1/Ph2NCT02230553 · Lapatinib Plus Trametinib in KRAS Mutant NSCLCThe Netherlands Cancer Institute · completed · Colorectal Cancer · study director
- Ph1/Ph2NCT02039336 · Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLCThe Netherlands Cancer Institute · completed · Colorectal Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in colorectal cancer.